List of Excipients in Branded Drug INDOCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	ALCOHOL
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	HYDROCHLORIC ACID
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	SODIUM HYDROXIDE
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	SORBIC ACID

Generic Drugs Containing INDOCIN

Company	Ingredient	NDC	Excipient
Iroko Pharmaceuticals LLC	indomethacin	42211-102	BUTYLATED HYDROXYANISOLE
Iroko Pharmaceuticals LLC	indomethacin	42211-102	BUTYLATED HYDROXYTOLUENE
Iroko Pharmaceuticals LLC	indomethacin	42211-102	EDETIC ACID
Iroko Pharmaceuticals LLC	indomethacin	42211-102	GLYCERIN

What are the Most Frequently-Used Excipients in INDOCIN?

# Of NDCs	Excipient
2	BUTYLATED HYDROXYANISOLE
2	BUTYLATED HYDROXYTOLUENE
2	EDETIC ACID
2	GLYCERIN

Indocin Excipient Strategy and Commercial Opportunities for Indomethacin Products

Last updated: August 22, 2026

Indocin is the branded formulation of indomethacin, a nonsteroidal anti-inflammatory drug used for acute and chronic inflammatory conditions. Its principal commercial opportunities are generic lifecycle management, pediatric and geriatric liquid formulations, taste-masked oral suspensions, rectal dosage forms, and excipient-enabled improvements in dissolution, stability, and gastrointestinal tolerability. The original product’s core composition and use patents are no longer the principal barriers to entry. Commercial value now depends on regulatory execution, supply reliability, formulation performance, and differentiated product positioning.

What products and dosage forms are marketed under Indocin?

Indocin has historically been marketed in several dosage forms containing indomethacin:

Product	Typical strength	Dosage form	Commercial relevance
Indocin capsules	25 mg, 50 mg	Immediate-release oral capsule	Primary generic competition
Indocin oral suspension	25 mg/5 mL	Oral liquid	Pediatric, geriatric, and swallowing-impaired patients
Indocin suppositories	50 mg	Rectal suppository	Alternative where oral dosing is impractical
Indocin IV	Indomethacin sodium formulation	Injectable	Historical hospital product; current availability requires product-specific verification

Indomethacin is a poorly water-soluble, lipophilic compound. The molecule’s low aqueous solubility, high gastrointestinal irritation potential, sensitivity to formulation variables, and relatively narrow therapeutic window create the main excipient opportunities.

The immediate-release capsule is technically mature. The greatest commercial differentiation is more likely in liquid, rectal, pediatric, and hospital-use products than in a conventional 25 mg or 50 mg capsule.

What excipient strategy is appropriate for Indocin capsules?

The capsule strategy should prioritize dissolution consistency, content uniformity, powder flow, capsule-fill performance, and chemical stability.

Core excipient functions

A conventional immediate-release indomethacin capsule may use:

• Lactose, microcrystalline cellulose, or dibasic calcium phosphate as diluents
• Povidone or other binders where wet or dry granulation is used
• Sodium starch glycolate, crospovidone, or croscarmellose sodium as disintegrants
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Gelatin or hypromellose for the capsule shell
• Titanium dioxide and approved colorants for shell identification

The commercial objective is not simply to increase dissolution. Excessive hydrophilic excipient loading can alter powder behavior, capsule robustness, and in vitro release without producing a clinically meaningful advantage. A formulation should be designed around the applicable immediate-release dissolution method and the target product profile established for the reference product.

Compatibility risks

Indomethacin formulation development should address:

1. Moisture exposure during granulation and storage.
2. Lubricant overmixing, which can reduce wetting and dissolution.
3. Interaction between the drug and reducing sugars or reactive excipients.
4. Polymorphic or crystallinity changes during processing.
5. Capsule-shell brittleness or cross-linking under unsuitable storage conditions.
6. Variability caused by particle-size distribution and electrostatic behavior.

A direct-compression formula can reduce process complexity, but it requires strong control of particle size, flow, segregation, and content uniformity. Roller compaction can improve manufacturability without introducing water, although ribbon density and redispersion must be controlled.

What excipients can improve indomethacin dissolution?

The most commercially relevant dissolution strategy is particle engineering combined with wetting or solubilizing excipients.

Particle-size reduction

Micronization can increase surface area and accelerate dissolution. It is a familiar strategy for generic development, but it creates risks involving:

• Agglomeration during blending
• Electrostatic charging
• Poor flow
• Content-uniformity failures
• Increased sensitivity to humidity
• Potential changes in powder handling at commercial scale

A micronized product is not automatically differentiated. The regulatory value comes from consistent bioequivalence performance, robust dissolution, or a lower manufacturing cost.

Wetting and surfactant systems

Low concentrations of surfactants may improve wetting and dissolution. Candidate systems include polysorbates, sodium lauryl sulfate, poloxamers, and other pharmaceutically accepted surfactants. The formulation must control surfactant concentration because excessive levels can affect gastrointestinal tolerability, dissolution discrimination, and bioequivalence.

Polymer and amorphous dispersion approaches

Solid dispersions using polymers such as povidone, copovidone, hydroxypropyl cellulose, or hypromellose acetate succinate may increase apparent solubility. These systems have limited attractiveness for a standard generic capsule because they introduce:

• More complex manufacturing
• Greater physical stability risk
• Potential recrystallization
• More extensive analytical characterization
• Higher cost of goods

A polymer-based formulation is more commercially defensible where it produces a measurable advantage in dissolution, dose uniformity, storage stability, or reduced variability.

Cyclodextrin complexes

Cyclodextrins can improve apparent solubility and may support liquid, injectable, or rapidly dissolving formulations. Their use is more commercially attractive in a differentiated dosage form than in a conventional capsule. The key constraints are excipient load, cost, tolerability, regulatory precedent, and the need to demonstrate a meaningful product advantage.

What excipients are most important for Indocin oral suspension?

The oral suspension is the clearest excipient-led opportunity. Indomethacin’s low water solubility requires a carefully controlled suspension rather than a simple aqueous solution.

A competitive suspension should address:

• Sedimentation rate
• Redispersibility
• Dose uniformity after storage
• Taste and mouthfeel
• Microbial preservation
• Chemical stability
• Pourability
• Device compatibility
• Administration through oral syringes and feeding tubes

Suspending systems

Potential suspending agents include xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose with carboxymethylcellulose sodium, hypromellose, and carbomer systems. The target is controlled viscosity that prevents rapid settling without making the product difficult to pour or withdraw through an oral syringe.

A high-viscosity suspension may improve physical stability but reduce dose recovery from the bottle or oral syringe. A low-viscosity suspension may be easier to administer but can produce rapid sedimentation and dose nonuniformity.

Wetting and dispersion

Wetting agents can improve particle dispersion and reduce floating or clumping. The selection should account for:

• Foam generation
• Taste
• Preservative compatibility
• Container adsorption
• Particle-size stability
• Compatibility with dosing devices

A structured vehicle using a wetting agent, suspending polymer, buffer, sweetener, and flavor system may be more robust than a single-polymer formula.

Taste masking

Indomethacin is intensely bitter. Taste masking is therefore a central commercial issue for pediatric and geriatric markets.

Potential approaches include:

• Ion-exchange resins
• Polymer coating of drug particles
• Lipid or wax-based coating
• Cyclodextrin complexation
• pH-mediated reduction of perceived bitterness
• Flavored suspending vehicles
• Multiparticulate systems dispersed in a palatable vehicle

Ion-exchange resins and polymer coatings can offer stronger taste masking than flavor-only systems. They also create additional development work because drug release must remain rapid after swallowing and must not be impaired by the coating or resin complex.

A successful taste-masked suspension could support a stronger product position than a conventional generic suspension, particularly where pediatric adherence and administration burden are procurement criteria.

What excipients are relevant to Indocin suppositories?

Indomethacin suppositories require a base that provides acceptable melting, drug dispersion, release, mechanical integrity, and storage stability.

Potential base categories include:

• Hard fat and hydrogenated vegetable-oil systems
• Synthetic triglyceride bases
• Polyethylene glycol bases
• Glycerinated gelatin systems, where technically suitable

Lipophilic bases may provide favorable comfort and release characteristics but can have variable behavior under warm storage conditions. Polyethylene glycol bases can improve physical stability but may produce different dissolution and local tolerability profiles.

The formulation should evaluate:

• Drug sedimentation during molding
• Content uniformity across the batch
• Softening time
• Breakage during handling
• Release in simulated conditions
• Stability under temperature excursions
• Packaging interaction
• Patient acceptability

Rectal products may have commercial value where patients cannot tolerate oral dosing or cannot swallow. Their market is narrower than oral capsules, but competition may also be less intense.

What patent opportunities exist for Indocin excipient formulations?

The original indomethacin composition-of-matter patent and early product patents are expired. New intellectual-property value would need to arise from a specific formulation, manufacturing process, delivery system, or use supported by technical data.

Formulation patents

Potential claim targets include:

• A defined particle-size distribution with a specific excipient ratio
• A taste-masked indomethacin suspension
• A physically stable suspension with defined sedimentation and redispersibility parameters
• A low-surfactant dissolution-enhancing composition
• A rectal formulation with controlled melting and release
• A tube-compatible liquid formulation
• A moisture-resistant capsule composition
• A solid dispersion with a defined polymer and crystallinity profile

Broad claims covering common excipients are vulnerable to prior-art and obviousness challenges. Stronger claims generally require a narrow combination, measurable performance threshold, and evidence of an unexpected result.

Manufacturing-process patents

Process claims may cover:

• Spray-drying or fluid-bed coating
• Solvent-mediated particle engineering
• Dry granulation under defined compaction conditions
• Controlled crystallization
• Continuous manufacturing
• Low-moisture encapsulation
• Drug layering onto carrier particles

Process patents can be commercially valuable when the method is difficult to design around or when the product’s critical quality attributes are linked to the process.

Method-of-use patents

New use patents may be possible only for a distinct, legally supportable indication or dosing regimen. They are less central to an excipient strategy and do not necessarily protect a generic formulation from all market entry if the generic product is approved for nonprotected uses.

When does Indocin lose exclusivity, and what is the Orange Book status?

Indocin’s primary small-molecule exclusivity has expired. Indomethacin is therefore exposed to conventional ANDA competition rather than biosimilar competition.

Exclusivity category	Indocin position
New chemical entity exclusivity	Expired
Core composition-of-matter patent	Expired
Conventional capsule entry	Generic pathway available
Oral suspension entry	Generic pathway available subject to product-specific requirements
Suppository entry	Generic pathway available subject to product-specific requirements
Biosimilar pathway	Not applicable
Orange Book strategy	Any remaining listed patents would be product- or indication-specific, not foundational

The FDA Orange Book remains the controlling source for current listed patents, pediatric exclusivity, and approved reference products. Product-specific verification is required because brand ownership, marketing status, and listed presentations can change over time (FDA, 2024a).

What Paragraph IV and generic launch risks exist for Indocin?

Paragraph IV risk is limited for the original Indocin product because its foundational exclusivity has ended. The relevant risks concern later-listed formulation or method-of-use patents, if any, rather than the indomethacin molecule itself.

For an ANDA sponsor, the main launch risks are:

1. Reference-product selection and discontinued-product complications.
2. Bioequivalence failure caused by poor dissolution or suspension variability.
3. Device or container differences for oral liquids.
4. Failure to match inactive-ingredient restrictions for a particular dosage form.
5. Patent claims directed to a narrow formulation.
6. Regulatory scrutiny of preservatives, colorants, or high-risk excipients.
7. Supply-chain disruption involving specialized coated particles or excipient grades.

A capsule sponsor can generally pursue a standard generic route. A suspension sponsor faces more technical risk because physical stability, dose uniformity, taste, and preservative effectiveness must be controlled together.

Is biosimilar competition relevant to Indocin?

No. Indomethacin is a synthetic small molecule, not a biologic. Competitive entry occurs through the abbreviated new drug application pathway, not the biosimilar pathway under section 351(k) of the Public Health Service Act.

The relevant competitive set includes:

• Generic indomethacin capsules
• Generic oral suspensions
• Generic suppositories
• Other NSAIDs, including ibuprofen, naproxen, diclofenac, and ketorolac
• Condition-specific alternatives such as colchicine or corticosteroids in selected indications

The strongest commercial differentiation is likely to come from dosage-form convenience and tolerability rather than molecular novelty.

Which commercial opportunities are strongest for Indocin excipients?

Pediatric and swallowing-impaired patient formulations

A palatable oral suspension with reliable dose delivery has the strongest excipient-led opportunity. Differentiation can come from taste masking, reduced shaking requirements, oral-syringe compatibility, and improved storage stability.

Hospital and institutional packaging

Unit-dose cups, ready-to-administer oral syringes, and feeding-tube-compatible packaging may improve institutional use. These products require container-closure, dose-recovery, and compatibility testing but can create procurement advantages.

Low-volume concentrated suspension

A more concentrated suspension could reduce administration volume. The technical challenge is maintaining uniformity and acceptable viscosity at a higher drug concentration. Any concentration change requires product-specific bioequivalence and dosing analysis.

Rectal dosage forms

Suppositories may retain value in patients unable to take oral medication. Improved mechanical strength, reduced leakage, and better storage performance could support institutional and specialty distribution.

Reformulated capsules

A conventional capsule has limited differentiation potential. The more defensible opportunities are low-cost, highly robust manufacturing or a technically distinctive dissolution-enhanced formulation that supports a new product position.

How strong is the patent estate for an Indocin excipient strategy?

The legacy Indocin patent estate is weak as a barrier to conventional generic entry because the core exclusivity period has ended. A new excipient strategy could create a moderate formulation patent position if it satisfies four conditions:

Criterion	Commercial test
Novelty	The exact excipient combination or process is not disclosed in prior art
Nonobviousness	The performance result is not predictable from routine formulation work
Enablement	The claims are supported across the claimed formulation range
Infringement detectability	The protected features can be identified from product testing or regulatory records

The strongest patent candidates are likely to be taste-masked suspensions, defined multiparticulate systems, and process-controlled formulations. A generic capsule containing standard diluents and disintegrants is unlikely to support a durable, high-value patent estate.

What licensing and partnership models are available?

Commercial partnerships can be structured around three assets:

1. An excipient technology, such as ion-exchange taste masking or polymer-coated indomethacin particles.
2. A finished dosage-form platform, such as a stable pediatric suspension.
3. A manufacturing process that reduces cost or improves batch consistency.

Potential counterparties include generic pharmaceutical companies, specialty pediatric manufacturers, hospital suppliers, and excipient technology companies. The most practical structure is often an exclusive field-of-use license combined with contract development and manufacturing support.

Royalty value depends on whether the technology provides:

• FDA-ready formulation data
• A validated analytical package
• Freedom-to-operate support
• A difficult-to-replicate process
• A clear target product profile
• Commercial scale-up history

What revenue exposure and market-entry scenarios apply?

Indocin revenue exposure is concentrated in products where formulation performance affects prescribing, adherence, or institutional administration.

Launch scenario	Likely competitive effect
Standard 25 mg capsule	Rapid price erosion and limited differentiation
Premium oral suspension	Moderate opportunity if taste and dose uniformity improve
Pediatric suspension	Higher value per unit, narrower market
Rectal suppository	Smaller market with potentially lower competitive density
Hospital unit-dose product	Procurement-driven opportunity
Novel delivery system	Greater patent potential but higher development cost

A standard generic capsule should be modeled as a volume and cost-efficiency business. A differentiated suspension should be modeled on higher gross margin, lower substitution risk, and a smaller eligible market. The commercial case is strongest when the formulation solves an observable administration problem rather than merely changing inactive ingredients.

Key Takeaways

• Indocin is the branded form of indomethacin, a small-molecule NSAID with expired foundational exclusivity.
• Biosimilar risk does not apply; competition occurs through generic drug pathways.
• Conventional capsules offer limited excipient-led differentiation.
• Oral suspension is the strongest opportunity for taste masking, dose uniformity, redispersibility, and pediatric positioning.
• Suppositories offer a narrower but potentially less crowded formulation market.
• New patents should focus on defined formulation combinations, measurable performance, or manufacturing processes.
• Standard excipient substitutions are unlikely to create a strong patent barrier.
• The main commercial risks are bioequivalence, suspension stability, preservative performance, packaging compatibility, and price erosion.
• Licensing value is highest for a validated, scale-ready formulation technology with a defensible patent position.

FAQs

Can indomethacin be formulated as a liquid without using a suspension?

A true aqueous solution is difficult because indomethacin has low water solubility. A solution may require pH adjustment, cosolvents, surfactants, complexation, or salt formation. A suspension is generally the more practical oral approach.

Which excipient is best for masking indomethacin bitterness?

No single excipient is universally optimal. Ion-exchange resins and polymer-coated particles can provide stronger masking than flavor systems alone, but the choice depends on release performance, stability, dose concentration, and regulatory acceptability.

Can a new Indocin suspension receive three years of FDA exclusivity?

A formulation change may qualify for regulatory exclusivity only if it meets the statutory requirements for a new drug application and contains a qualifying clinical investigation. An excipient change alone does not automatically create exclusivity.

Are indomethacin suppositories suitable for a 505(b)(2) strategy?

A 505(b)(2) approach may be relevant when a sponsor relies partly on existing findings for an approved product but introduces a meaningful change in dosage form, formulation, route, or clinical use. The applicable pathway depends on the proposed product and FDA determination.

What is the most defensible commercial claim for a new indomethacin excipient platform?

The strongest claim is usually a specific product-performance advantage, such as improved taste masking with maintained rapid release, superior suspension redispersibility, or stable dose delivery through an oral syringe. Generic claims covering routine excipient combinations are less defensible.

References

1. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. U.S. Food and Drug Administration. (2024b). Indomethacin prescribing information. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024c). Inactive ingredient database. U.S. Department of Health and Human Services.

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD.

5. DailyMed. (2024). Indomethacin capsule and oral suspension labeling. National Library of Medicine.

6. U.S. Food and Drug Administration. (2024d). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. U.S. Department of Health and Human Services.